Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | KDM5A | P29375 | 2/20 | 0.53 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.53 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | TET3 | O43151 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8880890 | 0.98 | KDM4E (0.52) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| (Chloromethyl)Benzene SCHEMBL27882366 | 0.85 | KDM4E (0.41) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL2046174 | 0.83 | KDM4E (0.38) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL3053770 | 0.83 | LMNA (0.39) | KDM4EKDM5AKDM3AJMJD1CKMO | |
| SCHEMBL2012751 | 0.81 | ALDH1A1 (0.45) | KDM4EKDM5AKDM3AJMJD1CKMO | |
| SCHEMBL2894784 | 0.81 | LMNA (0.57) | KDM4EKDM5AKDM3AJMJD1CTSHR | |
| SCHEMBL1505808 | 0.77 | KDM4E (0.57) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL24369081 | 0.76 | MAPT (0.39) | KDM4EKDM5AKDM3AJMJD1CTDP1 | |
| SCHEMBL18824618 | 0.76 | ALDH1A1 (0.39) | KDM4EALOX15ALDH1A1KDM4AMAPT | |
| SCHEMBL1427770 | 0.76 | RAB9A (0.43) | MAPTLMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775207-A | Morpholine-containing amide compound and preparation method and application thereof | 山东农业大学 | 2025-04-08 | — | — | CN | claimed |
| CN-111393376-B | Synthetic method of 2-chloropyrimidine-4-formic acid | 安徽赛迪生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112979559-A | 2-phenyl pyrimidine formic acid derivative and preparation method and application thereof | 沈阳药科大学 | 2021-06-18 | — | — | CN | claimed |
| WO-2021103256-A1 | CONTINUOUS SYNTHESIS METHOD FOR 2-CHLOROPYRIMIDINE-4-FORMIC ACID COMPOUND | 天津凯莱英制药有限公司 | 2021-06-03 | — | — | WO | claimed |
| CN-111393376-A | Synthetic method of 2-chloropyrimidine-4-formic acid | 安徽赛迪生物科技有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-110642789-B | Continuous synthesis method of 2-chloropyrimidine-4-formic acid compound | 天津凯莱英制药有限公司 | 2020-05-26 | — | — | CN | claimed |
| CN-110642789-A | Continuous synthesis method of 2-chloropyrimidine-4-formic acid compound | 天津凯莱英制药有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106083734-A | A kind of method preparing 2 chloropyrimide 4 formic acid | 安徽赛迪生物科技有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-5591853-A | CHEMICAL INTERMEDIATE PRODUCTS FOR PHARMACEUTICALS | LONZA LTD. (CH) | 1997-01-07 | — | — | US | claimed |
| EP-0552760-A1 | Microbiological process for the preparation of 2-halopyrimidine-4-carboxylic acids | LONZA AG (CH) | 1993-07-28 | — | — | EP | claimed |
| JP-5306273-A | — | — | None | — | — | JP | disclosed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2026047630-A1 | HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS | HETERO LABS LIMITED (IN) | 2026-03-05 | — | — | WO | disclosed |
| WO-1999002501-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| US-5591853-A | CHEMICAL INTERMEDIATE PRODUCTS FOR PHARMACEUTICALS | LONZA LTD. (CH) | 1997-01-07 | — | — | US | disclosed |
| US-5591853-A | CHEMICAL INTERMEDIATE PRODUCTS FOR PHARMACEUTICALS | LONZA LTD. (CH) | 1997-01-07 | — | — | US | disclosed |
| JP-H05306273-A | MICROBIOLOGICAL PRODUCTION OF 2-HALO-PYRIMIDINE-4-CARBOXYLIC ACID | LONZA AG | 1993-11-19 | — | — | JP | disclosed |
| EP-0552760-A1 | Microbiological process for the preparation of 2-halopyrimidine-4-carboxylic acids | LONZA AG (CH) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577229-B2 | Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors | CSF1R, CSF3R, AGER | KDM4E 348/4885KDM5A 191/4885KDM3A 295/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885KDM5A 4023/4885KDM3A 3750/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | KDM4E 1764/4885KDM5A 2020/4885KDM3A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.